Premium
Imidazole carboxamide therapy in advanced malignant melanoma
Author(s) -
Burke Peter J.,
McCarthy William H.,
Milton Gerald W.
Publication year - 1971
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(197103)27:3<744::aid-cncr2820270335>3.0.co;2-o
Subject(s) - medicine , melanoma , metastatic melanoma , imidazole , carboxamide , oncology , dermatology , cancer research , chemistry , biochemistry , organic chemistry
Twenty patients with metastatic malignant melanoma were treated with a new cytotoxic agent, 5‐(dimethyltriazeno) imidazole‐4‐carboxamide, in doses of 4.5 mg/kg body weight, daily for 10 days. An objective remission was observed in 4 out of 20 patients following the first course. No remissions were observed following subsequent courses. Toxic effects were minimal. Further evaluation of the use of this drug in the treatment of malignant melanoma appears justified.